Scalper1 News
Two biotech IPOs that launched Friday had to price below their estimated range in order to draw investors in, though the sector overall remains hot. There have been 60 initial public offerings in the health care sector this year, the most of any category, led by the biotech sector. Many biotechs, though, have priced below their estimated ranges. Innocoll (INNL), which develops absorbable collagen drugs to treat pain and foot infections, priced at Scalper1 News
Scalper1 News